Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant

Alyn H. Morice, Surinder S. Birring, Jaclyn A. Smith, Lorcan P. McGarvey, Jonathan Schelfhout, Allison Martin Nguyen, Zhi Jin Xu, Wen-Chi Wu, David R. Muccino, Mandel R. Sher

Open source

DOI
10.1007/s00408-021-00437-7
Published
2021-04
Container
Lung
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s00408-021-00437-7,
  title = {Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant},
  author = {Alyn H. Morice and Surinder S. Birring and Jaclyn A. Smith and Lorcan P. McGarvey and Jonathan Schelfhout and Allison Martin Nguyen and Zhi Jin Xu and Wen-Chi Wu and David R. Muccino and Mandel R. Sher},
  year = {2021},
  journal = {Lung},
  doi = {10.1007/s00408-021-00437-7},
  url = {https://doi.org/10.1007/s00408-021-00437-7}
}

RIS

TY  - JOUR
TI  - Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant
AU  - Alyn H. Morice
AU  - Surinder S. Birring
AU  - Jaclyn A. Smith
AU  - Lorcan P. McGarvey
AU  - Jonathan Schelfhout
AU  - Allison Martin Nguyen
AU  - Zhi Jin Xu
AU  - Wen-Chi Wu
AU  - David R. Muccino
AU  - Mandel R. Sher
PY  - 2021
JO  - Lung
DO  - 10.1007/s00408-021-00437-7
UR  - https://doi.org/10.1007/s00408-021-00437-7
ER  - 

APA

Morice, A. H., Birring, S. S., Smith, J. A., McGarvey, L. P., Schelfhout, J., Nguyen, A. M., Xu, Z. J., Wu, W., Muccino, D. R., & Sher, M. R. (2021). Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant. Lung. https://doi.org/10.1007/s00408-021-00437-7

Source records